Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
H Bleiberg, E Cvitkovic

Abstract

CPT-11 (Campto, irinotecan) is a promising new agent in the treatment of advanced colorectal cancer. Its safety has been assessed in light of the results from recent European phase II studies. In a pivotal French study in which CPT-11 350 mg/m2 was administered once every 3 weeks, neutropenia and delayed diarrhoea were the major adverse events: transient neutropenia occurred in 80% of patients, and severe neutropenia and febrile neutropenia in 47 and 15%, respectively. Delayed diarrhoea occurred in 87% of patients, with 39% having severe (grade 3 or 4) diarrhoea and 16% requiring hospitalisation. None of these adverse events was cumulative. Results of a pilot study to elucidate the mechanism of CPT-11-induced delayed diarrhoea suggest that this toxicity has a secretory mechanism with an exudative component. Early appropriate management of delayed diarrhoea may improve the safety profile of CPT-11. Indeed, the safety profile of CPT-11 was clearly improved in a later (currently ongoing) pan-European study: incidences of severe (grade 3 or 4) delayed diarrhoea and febrile neutropenia (+/-infection) were reduced from 39% to 23% (grade 4: 8% to 2.5%) and from 12% to 6%, respectively. Such an improvement could be attributed to a bett...Continue Reading

Citations

Jun 12, 2002·Current Treatment Options in Oncology·C F Verschraegen
Mar 12, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Masahiro AndoShoji Kudoh
Aug 17, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H Bleiberg
Feb 14, 2012·Journal of Ethnopharmacology·Shwu-Huey Liu, Yung-Chi Cheng
Jul 28, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·József ZsírosGiorgio Perilongo
May 19, 2012·Expert Review of Anticancer Therapy·Maria Ignez BraghiroliPaulo M Hoff
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarSomnath Sarkar
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarOliver Rosen
May 20, 2017·Cell Research·Paul Kurywchak, Raghu Kalluri
Jul 21, 2004·Journal of Psychopharmacology·Shufeng ZhouEdmund J D Lee
May 3, 2005·International Journal of Surgical Pathology·D SandmeierH Bouzourene
Jan 11, 2018·International Journal of Molecular Sciences·Risako KonKiyoshi Sugiyama
Oct 30, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael MichaelMalcolm J Moore
Apr 6, 2001·International Journal of Cancer. Journal International Du Cancer·Y TakedaK Kudo
Mar 23, 2001·Anti-cancer Drugs·D F KehrerA Sparreboom
Jun 19, 2001·American Journal of Clinical Oncology·M A Gil-DelgadoD Khayat
Oct 3, 1999·International Journal of Cancer. Journal International Du Cancer·K KobayashiH Fromm
Oct 23, 2016·Cancer Chemotherapy and Pharmacology·Bronwen J MayoDorothy M Keefe
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A SocinskiR B Natale
Apr 8, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Jinhua LuShengyou Lin
Oct 24, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·K FakihaJ M Bowen
Apr 16, 2019·Frontiers in Pharmacology·Liu TangHong Ding
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J Ratain
Aug 1, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jenna H BurtonYves Pommier
Jul 14, 2021·Colloids and Surfaces. B, Biointerfaces·Tao WangXinsong Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.